MIRA Pharmaceuticals, Inc. (MIRA) 10-Year Financial Performance & Capital Metrics

MIRA • • Industrial / General

HealthcareLarge PharmaEarly-Stage & Niche DevelopersClinical-Stage Pain & Specialty Developers

AboutMIRA Pharmaceuticals, Inc. operates as a clinical development stage biopharmaceutical company. The company focuses on the development and commercialization of a new molecular synthetic tetrahydrocannabinol (THC) analog under investigation for the treatment of adult patients with anxiety and cognitive decline typically associated with early-stage dementia. It is developing MIRA1a, a synthetic cannabinoid analog to treat anxiety and chronic pain by targeting the cannabinoid type 1 and type 2 receptors. The company was formerly known as MIRA1a Therapeutics, Inc. MIRA Pharmaceuticals, Inc. was incorporated in 2020 and is headquartered in Baltimore, Maryland.Show more

Revenue $0
EBITDA -$8M +6.0%
Net Income -$8M +34.5%
EPS (Diluted) -0.51 +21.5%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -238.9% +62.3%
ROIC -
Debt/Equity -
Interest Coverage -48.40 -1862.0%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Share count reduced 16.8% through buybacks

✗Weaknesses

✗Weak Piotroski F-Score: 3/9
✗Trading more than 30% below 52-week high
✗Expensive at 10.3x book value
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-152.8%

EPS CAGR

10Y-

5Y-

3Y-

TTM-111.84%

ROCE

10Y Avg-421.86%

5Y Avg-421.86%

3Y Avg-497.06%

Latest-243.94%

Peer Comparison

Clinical-Stage Pain & Specialty Developers

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
SRXHSRx Health Solutions Inc.	13.22M	0.19	-0.21	28.4%	-9.36%		11.92%
SCLXScilex Holding Company	80.6M	11.46	-0.59	21.07%	-9.31%		24.01%
MIRAMIRA Pharmaceuticals, Inc.	61.14M	1.46	-2.86			-376.4%
CTORCitius Oncology, Inc.	91.58M	1.08	-3.18			-55.19%		0.08

Profit & Loss

	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	0	0	0
Revenue Growth %	-	-	-	-	-
Cost of Goods Sold+	0	0	0	0	0
COGS % of Revenue	-	-	-	-	-
Gross Profit+	0	0	0	0	0
Gross Margin %	-	-	-	-	-
Gross Profit Growth %	-	-	-	-	-
Operating Expenses+	67.63K	2.15M	7.05M	8.53M	8.02M
OpEx % of Revenue	-	-	-	-	-
Selling, General & Admin	52.98K	770.12K	2.99M	6.5M	4.71M
SG&A % of Revenue	-	-	-	-	-
Research & Development	14.65K	684.45K	2.35M	1.57M	3.31M
R&D % of Revenue	-	-	-	-	-
Other Operating Expenses	0	697.6K	1.7M	453.55K	0
Operating Income+	-67.63K	-2.15M	-7.05M	-8.53M	-8.02M
Operating Margin %	-	-	-	-	-
Operating Income Growth %	-	-30.82%	-2.27%	-0.21%	0.06%
EBITDA+	-67.63K	0	0	-8.53M	-8.02M
EBITDA Margin %	-	-	-	-	-
EBITDA Growth %	-	1%	-	-	0.06%
D&A (Non-Cash Add-back)	0	2.15M	7.05M	0	-2
EBIT	-67.63K	-2.15M	-7.05M	-8.53M	-8.02M
Net Interest Income+	-364	-24.37K	-10.25K	-3.46M	-165.67K
Interest Income	0	0	0	0	0
Interest Expense	364	24.37K	10.25K	3.46M	165.67K
Other Income/Expense	-364	-24.37K	-10.25K	-3.46M	165.67K
Pretax Income+	-67.99K	-2.18M	-7.06M	-11.98M	-7.85M
Pretax Margin %	-	-	-	-	-
Income Tax+	0	0	0	0	0
Effective Tax Rate %	1%	1%	1%	1%	1%
Net Income+	-67.99K	-2.18M	-7.06M	-11.98M	-7.85M
Net Margin %	-	-	-	-	-
Net Income Growth %	-	-31.01%	-2.24%	-0.7%	0.34%
Net Income (Continuing)	-67.99K	-2.18M	-7.06M	-11.98M	-7.85M
Discontinued Operations	0	0	0	0	0
Minority Interest	0	0	0	0	0
EPS (Diluted)+	-0.00	-0.15	-0.48	-0.65	-0.51
EPS Growth %	-	-	-2.2%	-0.35%	0.22%
EPS (Basic)	-0.00	-0.15	-0.48	-0.65	-0.51
Diluted Shares Outstanding	14.75M	14.75M	14.75M	18.57M	15.44M
Basic Shares Outstanding	14.75M	14.75M	14.75M	18.57M	15.44M
Dividend Payout Ratio	-	-	-	-	-

Balance Sheet

	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	3.49K	2.91M	494.4K	4.86M	2.89M
Cash & Short-Term Investments	3.49K	2.81M	350.98K	4.6M	2.83M
Cash Only	3.49K	2.81M	350.98K	4.6M	2.83M
Short-Term Investments	0	0	0	0	0
Accounts Receivable	0	0	0	0	0
Days Sales Outstanding	-	-	-	-	-
Inventory	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-
Other Current Assets	0	100K	143.43K	11.86K	0
Total Non-Current Assets+	18.88K	445.61K	363.67K	74.21K	35.44K
Property, Plant & Equipment	0	0	363.67K	5.06K	0
Fixed Asset Turnover	-	-	-	-	-
Goodwill	0	0	0	0	0
Intangible Assets	0	0	0	0	0
Long-Term Investments	0	0	0	0	35.44K
Other Non-Current Assets	18.88K	445.61K	0	69.15K	0
Total Assets+	22.37K	3.36M	858.07K	4.93M	2.92M
Asset Turnover	-	-	-	-	-
Asset Growth %	-	148.98%	-0.74%	4.75%	-0.41%
Total Current Liabilities+	90.36K	1.09M	1.37M	558.1K	723.35K
Accounts Payable	0	228.41K	905.55K	538.56K	723.35K
Days Payables Outstanding	-	-	-	-	-
Short-Term Debt	90K	293.06K	133.06K	0	0
Deferred Revenue (Current)	0	0	0	0	0
Other Current Liabilities	0	0	0	0	0
Current Ratio	0.04x	2.66x	0.36x	8.70x	3.99x
Quick Ratio	0.04x	2.66x	0.36x	8.70x	3.99x
Cash Conversion Cycle	-	-	-	-	-
Total Non-Current Liabilities+	0	0	84.27K	0	0
Long-Term Debt	0	0	0	0	0
Capital Lease Obligations	0	0	84.27K	0	0
Deferred Tax Liabilities	0	0	0	0	0
Other Non-Current Liabilities	0	0	0	0	0
Total Liabilities	90.36K	1.09M	1.45M	558.1K	723.35K
Total Debt+	90K	293.06K	491.23K	5.06K	0
Net Debt	86.51K	-2.52M	140.25K	-4.6M	-2.83M
Debt / Equity	-	0.13x	-	0.00x	-
Debt / EBITDA	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-
Interest Coverage	-185.79x	-88.30x	-687.60x	-2.47x	-48.40x
Total Equity+	-67.99K	2.26M	-596.23K	4.37M	2.2M
Equity Growth %	-	34.26%	-1.26%	8.34%	-0.5%
Book Value per Share	-0.00	0.15	-0.04	0.24	0.14
Total Shareholders' Equity	-67.99K	2.26M	-596.23K	4.37M	2.2M
Common Stock	5.89K	6.34K	6.66K	1.48K	1.66K
Retained Earnings	-67.99K	-2.24M	-9.3M	-21.29M	-29.14M
Treasury Stock	0	0	0	0	0
Accumulated OCI	-5.89K	0	0	0	0
Minority Interest	0	0	0	0	0

Cash Flow

	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-67.99K	-1.38M	-5.6M	-4.53M	-5.56M
Operating CF Margin %	-	-	-	-	-
Operating CF Growth %	-	-19.24%	-3.07%	0.19%	-0.23%
Net Income	-67.99K	-2.18M	-7.06M	-11.98M	-7.85M
Depreciation & Amortization	0	0	0	0	0
Stock-Based Compensation	0	0	1.3M	2.55M	0
Deferred Taxes	0	0	0	0	0
Other Non-Cash Items	0	24.37K	10.25K	5.54M	1.92M
Working Capital Changes	0	776.01K	146.58K	-639.69K	371.25K
Change in Receivables	0	0	0	-11.86K	11.86K
Change in Inventory	0	0	0	0	0
Change in Payables	0	0	0	-389.52K	184.78K
Cash from Investing+	0	0	0	0	0
Capital Expenditures	0	0	0	0	0
CapEx % of Revenue	-	-	-	-	-
Acquisitions	-	-	-	-	-
Investments	-	-	-	-	-
Other Investing	0	0	0	0	0
Cash from Financing+	71.12K	4.18M	3.15M	8.78M	3.79M
Debt Issued (Net)	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-
Dividends Paid	0	0	0	0	0
Share Repurchases	-	-	-	-	-
Other Financing	-18.88K	-520.85K	402.19K	74.28K	182.42K
Net Change in Cash	-	-	-	-	-
Free Cash Flow+	-67.99K	-1.38M	-5.6M	-4.53M	-5.56M
FCF Margin %	-	-	-	-	-
FCF Growth %	-	-19.24%	-3.07%	0.19%	-0.23%
FCF per Share	-0.00	-0.09	-0.38	-0.24	-0.36
FCF Conversion (FCF/Net Income)	1.00x	0.63x	0.79x	0.38x	0.71x
Interest Paid	0	0	0	0	0
Taxes Paid	0	0	0	0	0

Key Ratios

Metric	2020	2021	2022	2023	2024
Return on Equity (ROE)	-	-198.47%	-847.77%	-634.3%	-238.9%
Debt / Equity	-	0.13x	-	0.00x	-
Interest Coverage	-185.79x	-88.30x	-687.60x	-2.47x	-48.40x
FCF Conversion	1.00x	0.63x	0.79x	0.38x	0.71x

Frequently Asked Questions

Growth & Financials

MIRA Pharmaceuticals, Inc. (MIRA) grew revenue by 0.0% over the past year. Growth has been modest.

MIRA Pharmaceuticals, Inc. (MIRA) reported a net loss of $28.4M for fiscal year 2024.

Dividend & Returns

MIRA Pharmaceuticals, Inc. (MIRA) has a return on equity (ROE) of -238.9%. Negative ROE indicates the company is unprofitable.

MIRA Pharmaceuticals, Inc. (MIRA) had negative free cash flow of $5.3M in fiscal year 2024, likely due to heavy capital investments.

← Back to Screener